SCHEMBL6076954

SCHEMBL6076954

CSc1cc(F)ccc1CNC=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 2/20 0.39
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
ADRA1D P25100 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37
LMNA P02545 2/20 0.35
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH7 P40394 1/20 0.34
CHRM2 P08172 1/20 0.34
MAPT P10636 2/20 0.32
MEN1 O00255 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
ATM Q13315 2/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076963 0.80 SLC6A4 (0.44) DDR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL1150906 0.79 DDR1 (0.34) DDR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL19017833 0.78 P2RX7 (0.43) LMNAADH1BADH1CADH1AADH7
SCHEMBL5541864 0.78 IDO1 (0.44) ADH1BADH1CADH1AADH7KDM4E
SCHEMBL17689059 0.77 DDR1 (0.39) DDR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL513576 0.76 CHRM2 (0.57) LMNAADH1BADH1CADH1AADH7
SCHEMBL6076450 0.75 ADRA2A (0.38) DDR1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL17574522 0.75 P2RX7 (0.45) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL10566150 0.75 HTR2A (0.40) LMNAADH1BADH1CADH1AADH7
Hydrochloric Acid SCHEMBL6077356 0.74 ADRA2A (0.37) DDR1ADRA2AADRA2BADRA2CADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF DDR1 3524/4885ADRA2A 3838/4885ADRA2B 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.